ROCKLAND, Mass.--(BUSINESS WIRE)--EMD Serono, Inc., an affiliate of Merck KGaA, Darmstadt, Germany, today announced that new data from the company’s multiple sclerosis (MS) portfolio will be presented at the 63rd Annual Meeting of the American Academy of Neurology (AAN) taking place from April 9 to 16, in Honolulu, Hawaii. The data presented will focus on Rebif® (interferon beta-1a), an established therapy for relapsing forms of MS, and Cladribine Tablets, an oral short-course disease-modifying therapy currently approved and available under the trade name Movectro® in Australia and Russia as a treatment of relapsing-remitting MS and under regulatory review in Canada and other countries. In the United States, the company received a complete response letter from the Food and Drug Administration on Cladribine Tablets on February 28 and has requested an end-of-review meeting to discuss next steps.
